EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL

By Insights from 2024 EHA Annual Meeting FEATURING Stephen S. Opat

0 views

July 3, 2024

Comments 0

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs